Critical Contrast: Laboratory Corp. of America (NYSE:LH) and Centogene (NYSE:CNTG)

Laboratory Corp. of America (NYSE:LH) and Centogene (NASDAQ:CNTG) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Valuation and Earnings

This table compares Laboratory Corp. of America and Centogene’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Laboratory Corp. of America $11.55 billion 1.15 $823.80 million $11.32 12.11
Centogene $47.81 million 7.06 -$12.95 million N/A N/A

Laboratory Corp. of America has higher revenue and earnings than Centogene.

Profitability

This table compares Laboratory Corp. of America and Centogene’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Laboratory Corp. of America 7.13% 15.37% 6.32%
Centogene N/A N/A N/A

Institutional and Insider Ownership

91.5% of Laboratory Corp. of America shares are held by institutional investors. Comparatively, 8.3% of Centogene shares are held by institutional investors. 0.7% of Laboratory Corp. of America shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Laboratory Corp. of America and Centogene, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Laboratory Corp. of America 2 3 9 0 2.50
Centogene 0 0 4 0 3.00

Laboratory Corp. of America currently has a consensus price target of $197.54, suggesting a potential upside of 44.14%. Centogene has a consensus price target of $16.67, suggesting a potential downside of 1.96%. Given Laboratory Corp. of America’s higher probable upside, equities research analysts clearly believe Laboratory Corp. of America is more favorable than Centogene.

Summary

Laboratory Corp. of America beats Centogene on 9 of the 11 factors compared between the two stocks.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, and medical drug monitoring; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides technology-enabled solutions, including a suite of applications to enable patients, healthcare providers, health systems, accountable care organizations, and insurers with convenient and secure access to LCD's data and services, as well as billing for laboratory services. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, academic institutions, and independent clinical laboratories. Laboratory Corporation of America Holdings has collaborations with the Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, Yale University, and QIAGEN N.V. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

Centogene Company Profile

Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene B.V. was founded in 2006 and is headquartered in Rostock, Germany.

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.